Clinical Trials Logo

Cetuximab clinical trials

View clinical trials related to Cetuximab.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04509635 Not yet recruiting - Colorectal Cancer Clinical Trials

Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis

Start date: September 1, 2020
Phase: Phase 3
Study type: Interventional

For patients with unresectable colorectal cancer liver metastases, preclinical studies have shown that after the resistance of cetuximab, the treatment sensitivity can be restored by stopping cetuximab for a period of time. This is called the cetuximab re-challenge. And the circulating tumor DNA (ctDNA) test is reported a biomarker for the efficacy of cetuximab rechallenge. However, there is still no randomized controlled trial for verification. This study aims at patients after the first-line treatment of cetuximab has progressed. After the second-line non-cetuximab treatment has progressed, the effects of re-application of combined with cetuximab and chemotherapy alone are compared to verify the re-challenge effect.